GSK
GSK
809 hedge funds and large institutions have $9.7B invested in GSK in 2023 Q1 according to their latest regulatory filings, with 82 funds opening new positions, 352 increasing their positions, 219 reducing their positions, and 70 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 352 | Existing positions reduced: 219
61% more call options, than puts
Call options by funds: $269M | Put options by funds: $167M
17% more first-time investments, than exits
New positions opened: 82 | Existing positions closed: 70
0.18% less ownership
Funds ownership: 13.5% → 13.32% (-0.18%)
1% less funds holding
Funds holding: 815 → 809 (-6)
10% less capital inflows, than outflows
Capital inflows: $1.05B | Capital outflows: $1.17B
19% less funds holding in top 10
Funds holding in top 10: 16 → 13 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$214M |
| 2 |
Dodge & Cox
San Francisco,
California
|
+$167M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$55.1M |
| 4 |
Holocene Advisors
New York
|
+$41.4M |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$33.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$223M |
| 2 |
JTC Employer Solutions Trustee
St Helier,
Jersey
|
-$139M |
| 3 |
Millennium Management
New York
|
-$119M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$112M |
| 5 |
Renaissance Technologies
New York
|
-$73.7M |
GSK Hedge Fund Activity: Q1 2023 in Review
809 of the 6,290 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2023, worth a combined $9.7B — down 0.31% from $9.7B a quarter earlier.
Buyers outnumbered sellers: 82 funds opened new GSK positions and 70 closed out — a net gain of 12 holders — while 352 added to existing stakes and 219 trimmed.
The largest buyer was Primecap Management, adding an estimated $214M. The largest seller was Point72 Asset Management, cutting an estimated $223M.
- 809 institutional investors held GSK (GSK) as of Q1 2023, down from 815 in Q4 2022.
- Funds reported $9.7B of GSK stock for Q1 2023, down 0.31% quarter-over-quarter.
- 82 funds opened new GSK positions in Q1 2023 and 70 closed out, a net change of +12 holders.
- The largest GSK buyer in Q1 2023 was Primecap Management, an estimated $214M added.
- The largest GSK seller in Q1 2023 was Point72 Asset Management, an estimated $223M sold.
Based on aggregated 13F filings for Q1 2023.